Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed breast cancer and candidate for adjuvant or neoadjuvant chemotherapy~* Candidate for docetaxel and cyclophosphamide chemotherapy~* Female or male at least 18 years of age~* Eastern Cooperative Oncology Group (ECOG) ≤ 2~* Absolute neutrophil count (ANC) ≥ 1.5×109/L~* Platelet count ≥ 100 x 10\^9/L~* Creatinine ≤ 1.5 x upper limit of normal (ULN)~* Total bilirubin ≤1.5 mg/dL(≤ 25.65 μmol/L).~* Aspartate aminotransferase per serum glutamic-oxaloacetic transaminase (AST/SGOT) and/or alanine aminotransferase per serum glutamic-pyruvic transaminase (ALT/SGPT) ≤ 2.5 x ULN~* Hemoglobin \> 9 g/dL~* Alkaline phosphatase ≤ 1.5 x ULN~Exclusion Criteria:~* Known sensitivity to E. coli-derived products or known sensitivity to any of the products to be administered~* Known Human Immunodeficiency Virus (HIV) infection~* Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) diagnosis with detectable viral load or immunological evidence of chronic active disease~* Active infection or any serious underlying medical condition that would impair ability to receive protocol treatment~* Prior bone marrow or stem cell transplant~* Prolonged exposure to glucocorticosteroids and immunosuppressive agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: SPI-2012 45 µg/kg and Docetaxel + Cyclophosphamide (TC) (Type: EXPERIMENTAL): Participants received SPI-2012 45 microgram/kilogram (µg/kg), subcutaneously (SC) once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 milligram/ square metre (mg/m\^2) intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes.
- Arm 2: SPI-2012 135 µg/kg and Docetaxel + Cyclophosphamide (TC) (Type: EXPERIMENTAL): Participants received SPI-2012 135 µg/kg, SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 mg/m\^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes.
- Arm 3: SPI-2012 270 µg/kg and Docetaxel + Cyclophosphamide (TC) (Type: EXPERIMENTAL): Participants received SPI-2012 270 µg/kg, SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 mg/m\^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes.
- Arm 4: Pegfilgrastim and Docetaxel + Cyclophosphamide (TC) (Type: EXPERIMENTAL): Participants received Pegfilgrastim 6 milligram (mg), SC once per cycle on Day 2 of each cycle up to cycle 4 (each cycle was 21 days), approximately 24 hours after the administration of TC chemotherapy. TC chemotherapy was administered on Day 1 of each cycle as follows:~Docetaxel 75 mg/m\^2 intravenous (IV) infusion over 60 minutes and Cyclophosphamide 600 mg/m\^2 IV infusion over 30-60 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).